Clinuvel Pharmaceuticals Limited

ASX CUV.AX

Clinuvel Pharmaceuticals Limited Return on Equity (ROE) for the year ending June 30, 2024: 17.55%

Clinuvel Pharmaceuticals Limited Return on Equity (ROE) is 17.55% for the year ending June 30, 2024, a -5.57% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Clinuvel Pharmaceuticals Limited Return on Equity (ROE) for the year ending June 30, 2023 was 18.59%, a 11.80% change year over year.
Clinuvel Pharmaceuticals Limited Return on Equity (ROE) for the year ending June 30, 2022 was 16.63%, a -33.60% change year over year.
Clinuvel Pharmaceuticals Limited Return on Equity (ROE) for the year ending June 30, 2021 was 25.04%, a 8.42% change year over year.
Clinuvel Pharmaceuticals Limited Return on Equity (ROE) for the year ending June 30, 2020 was 23.10%, a -27.16% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

ASX: CUV.AX

Clinuvel Pharmaceuticals Limited

CEO	Dr. Philippe Jacques Wolgen M.B.A., M.D.
IPO Date	Feb. 11, 2001
Location	Australia
Headquarters	535 Bourke Street
Employees	16
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Key trends

Past 5 years